FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

32 letters match. Newest first.

  1. Eurofins SF Analytical Laboratories, Inc.

    FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.

    High risk
  2. Auriga Research Pvt. Ltd.

    Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.

    High risk
  3. Laboratorios Dr. Collado S.A.

    FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.

    High risk
  4. Microbiological Testing & Consulting, LLC

    FDA warned contract testing lab Microbiological Testing & Consulting over CGMP violations in drug product microbiological testing.

    High risk
  5. Tentamus India Private Limited

    FDA warned India-based contract testing lab Tentamus over destroyed and backdated lab records and limited inspection access.

    High risk
  6. HTO Nevada, Inc. dba Kirkman

    HTO Nevada dba Kirkman, an OTC drug contract manufacturer, was cited for CGMP violations including mislabeled reformulated drugs.

    High risk
  7. Medinatura New Mexico, Inc.

    FDA cited Medinatura New Mexico for drug manufacturing rule violations, including weak component testing and cleaning.

    High risk
  8. Rhyz Analytical Labs

    FDA warned Rhyz Analytical Labs, a contract drug testing lab, that inadequate microbial failure investigations and quality oversight made tested drugs adulterated.

    High risk
  9. Siddha Flower Essences, LLC., dba Siddha Remedies

    FDA cites Siddha Remedies, a maker of children's homeopathic drugs, for untested water and botanicals and microbial contamination.

    High risk
  10. BRS Analytical Services, LLC

    BRS Analytical Services, LLC made sterile OTC drugs in an unsuitable aseptic facility and recalled them over sterility assurance.

    High risk
  11. Chromatography Institute of America dba Compounder’s International Analytical Laboratory

    FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.

    High risk
  12. Jiangsu Kerbio Medical Technology Group Co.

    FDA cites Jiangsu Kerbio Medical Technology Group for serious GLP violations in medical device safety testing.

    High risk
  13. Shiva Analyticals Private Limited

    FDA warned Shiva Analyticals, an Indian contract drug testing lab, that inadequate OOS investigations and data integrity failures adulterated tested drugs.

    High risk
  14. Yangzhou Sion Commodity Co., Ltd.

    FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.

    High risk
  15. Advanced Pharmaceutical Technology

    FDA warns Advanced Pharmaceutical Technology over drug manufacturing quality failures, sterility controls, and unapproved drugs.

    High risk
  16. ABR Laboratory LLC

    FDA warned ABR Laboratory, a contract drug testing lab, that unverified microbial test methods and missed investigations made tested drugs adulterated.

    High risk
  17. Center for Instrumental Analysis of China Pharmaceutical University

    Center for Instrumental Analysis of China Pharmaceutical University cited for incomplete API testing records and no quality unit.

    High risk
  18. Analytical Food Laboratories, Inc.

    FDA warned contract testing lab Analytical Food Laboratories after inspection found unvalidated drug test methods and weak quality oversight.

    High risk
  19. Outin Futures Corp.

    FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.

    High risk
  20. Fancystage Unipessoal, LDA

    FDA warned Portugal OTC drug maker Fancystage Unipessoal of repeated CGMP failures, untested ingredients, unvalidated processes and misbranded fluoride mouthwash.

    High risk
  21. Grupo Quimico SRL

    FDA warns Uruguay contract testing lab Grupo Quimico over data integrity failures, including unreported failing HPLC results.

    High risk
  22. Cohere Beauty

    FDA cites Cohere Beauty for unvalidated OTC drug manufacturing and inadequate quality oversight at its Santa Fe Springs facility.

    Medium
  23. Sure-Biochem Laboratories, LLC

    FDA says contract lab Sure-Biochem missed Burkholderia cepacia in drug samples and cites broad CGMP failures.

    High risk
  24. DuPont Nutrition USA Inc.

    FDA found DuPont released Avicel excipient that failed conductivity limits, citing weak investigations and data integrity lapses.

    High risk
  25. Green Wave Analytical, LLC

    FDA warned Green Wave Analytical, a contract drug testing lab, over quality violations and its denied inspection access.

    High risk
  26. Miami University Department of Chemistry and Biochemistry

    Miami University contract testing lab falsified heparin API test data and lacked CGMP controls.

    High risk
  27. The W.S. Badger Company, Inc.

    FDA warned W.S. Badger over repeat manufacturing-quality failures in OTC drug products, including sunscreen process, cleaning, test-method, and OOS investigation problems.

    High risk
  28. Vitae Enim Vitae Scientific Inc.

    FDA warned Vitae Enim Vitae Scientific of sterile drug CGMP violations and contamination-control failures after a 2021 inspection, leading to a recall.

    High risk
  29. Accu Bio-Chem Laboratories

    FDA warned Accu Bio-Chem Laboratories, a contract OTC drug-testing lab, over inadequate failing-result investigations, method verification, and data controls.

    Medium
  30. Adamson Analytical Laboratories, Inc.

    FDA warned California contract drug-testing lab Adamson over inadequate computer controls and data integrity failures.

    High risk
  31. Missouri Analytical Laboratories Inc

    Missouri Analytical Laboratories, a contract drug testing lab, cited for manufacturing practice violations including inadequate out-of-specification investigations and data integrity failures.

    High risk
  32. Maitland Labs of Central Florida

    FDA warns Maitland Labs of Central Florida over sterile compounded drugs with manufacturing quality failures, mislabeling, and unapproved new drug violations.

    High risk